6 completed, 2 terminated. 5 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
| Phase 2 | 3 | Terminated 2, Completed 1 |
Follow UCB Celltech: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Relative Bioavailability and Tolerability of Bimekizumab in Healthy Subjects Bimekizumab - Healthy Volunteers | Phase 1 | Completed | UCB Celltech | 12 | 2016-03-04 | 2021-08-31 |
| UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome UCB5857, Placebo - Primary Sjögren's Syndrome | Phase 2 | Terminated | UCB Celltech | 27 | 2015-10-01 | 2020-12-01 |
| Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis Bimekizumab, Certolizumab Pegol, Placebo - Rheumatoid Arthritis | Phase 2 | Completed | UCB Celltech | 159 | 2015-04-01 | 2017-05-31 |
| Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of UCB5857 in Healthy Subjects UCB5857, Placebo - Healthy Volunteers | Phase 1 | Completed | UCB Celltech | 60 | 2014-08-01 | 2015-03-05 |
| A First-In-Human Study With a Single Dose UCB7665 in Healthy Volunteers UCB7665 Intravenous 1, UCB7665 Intravenous 2, UCB7665 Intravenous 3 - Healthy | Phase 1 | Completed | UCB Celltech | 41 | 2014-07-01 | 2015-10-05 |
| Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis UCB4940 40 mg, UCB4940 80 mg, UCB4940 160 mg - Psoriatic Arthritis | Phase 1 | Completed | UCB Celltech | 53 | 2014-05-01 | 2015-09-01 |
| A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of UCB4940 in Patients With Psoriasis UCB4940, Placebo - Mild to Moderate Psoriasis | Phase 1 | Completed | UCB Celltech | 39 | 2012-11-01 | 2015-08-20 |
| The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents Certolizumab Pegol - Crohn's Disease | Phase 2 | Terminated | UCB Celltech | 99 | 2009-04-01 | 2018-08-07 |
Arthritis, Psoriatic (1) · Arthritis, Rheumatoid (1) · Crohn Disease (1) · Psoriasis (1)
bimekizumab (4) · Certolizumab Pegol (2)
United Kingdom (7) · Moldova (2) · Australia (1) · Bulgaria (1) · Canada (1) · Czechia (1) · France (1) · Hungary (1) · Italy (1) · New Zealand (1) · Poland (1) · Russia (1) · Slovakia (1) · Spain (1) · Sweden (1)
PMID 27859546, PMID 29093180, PMID 29275332, PMID 31177099, PMID 32949140
2014 (4)